文献速递临床试验与 GCP流行病学与生物统计

SGLT2抑制剂在射血分数降低心衰患者中的应用:EMPEROR-Reduced与DAPA-HF试验的荟萃分析

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
PubMed 文献 · Lancet · 2020-08-30

该预设荟萃分析合并DAPA-HF与EMPEROR-Reduced两项试验共8474例HFrEF患者数据,评估SGLT2抑制剂对全因死亡、心血管死亡、心衰住院及肾脏结局的影响。

要点

  • SGLT2抑制剂降低HFrEF患者全因死亡13%、心血管死亡14%。
  • 心血管死亡或首次心衰住院复合风险降低26%,复发事件复合风险降低25%。

核心结论

  • 恩格列净与达格列净对心衰住院的效应在两项独立试验中一致,并提示可改善肾脏结局、降低全因死亡和心血管死亡。

研究设计与样本

  • 预设荟萃分析纳入DAPA-HF(达格列净)与EMPEROR-Reduced(恩格列净)两项评估SGLT2抑制剂对HFrEF患者心血管结局影响的大规模试验,合并8474例患者。
  • 主要终点为全因死亡时间,另评估预设亚组中心血管死亡或心衰住院复合风险的治疗效应。
  • 采用Cox比例风险模型推导风险比(HR),Cochran Q检验评估治疗交互作用,Lin-Wei-Yang-Ying模型推导复发事件的率比。

关键数值与推荐

  • 基于年龄、性别、糖尿病、ARNI治疗及基线eGFR的亚组显示一致获益。
  • 基于NYHA功能分级和种族的亚组提示存在治疗-by-亚组交互作用。

临床怎么用

  • 对于HFrEF患者,无论是否合并糖尿病,SGLT2抑制剂(恩格列净或达格列净)可考虑用于降低心衰住院、心血管死亡及全因死亡风险。
  • SGLT2抑制剂治疗可能同时改善肾脏复合终点,支持在HFrEF患者中综合评估心肾获益。

局限性

  • 分析基于两项试验的研究水平(DAPA-HF)与患者水平(EMPEROR-Reduced)数据合并。
  • NYHA功能分级和种族亚组提示治疗交互作用,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure with reduced ejection fraction (HFrEF) with or without diabetes. However, neither trial was powered to assess effects on cardiovascular death or all-cause death or to characterise effects in clinically important subgroups. Using study-level published data from DAPA-HF and patient-level data from EMPEROR-Reduced, we aimed to estimate the effect of SGLT2 inhibition on fatal and non-fatal heart failure events and renal outcomes in all randomly assigned patients with HFrEF and in relevant subgroups from DAPA-HF and EMPEROR-Reduced trials. METHODS: We did a prespecified meta-analysis of the two single large-scale trials assessing the effects of SGLT2 inhibitors on cardiovascular outcomes in patients with HFrEF with or without diabetes: DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin). The primary endpoint was time to all-cause death. Additionally, we assessed the effects of treatment in prespecified subgroups on the combined risk of cardiovascular death or hospitalisation for heart failure. These subgroups were based on type 2 diabetes status, age, sex, angiotensin receptor neprilysin inhibitor (ARNI) treatment, New York Heart Association (NYHA) functional class, race, history of hospitalisation for heart failure, estimated glomerular filtration rate (eGFR), body-mass index, and region (post-hoc). We used hazard ratios (HRs) derived from Cox proportional hazard models for time-to-first event endpoints and Cochran's Q test for treatment interactions; the analysis of recurrent events was based on rate ratios derived from the Lin-Wei-Yang-Ying model. FINDINGS: Among 8474 patients combined from both trials, the estimated treatment effect was a 13% reduction in all-cause death (pooled HR 0·87, 95% CI 0·77-0·98; p=0·018) and 14% reduction in cardiovascular death (0·86, 0·76-0·98; p=0·027). SGLT2 inhibition was accompanied by a 26% relative reduction in the combined risk of cardiovascular death or first hospitalisation for heart failure (0·74, 0·68-0·82; p<0·0001), and by a 25% decrease in the composite of recurrent hospitalisations for heart failure or cardiovascular death (0·75, 0·68-0·84; p<0·0001). The risk of the composite renal endpoint was also reduced (0·62, 0·43-0·90; p=0·013). All tests for heterogeneity of effect size between trials were not significant. The pooled treatment effects showed consistent benefits for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested treatment-by-subgroup interactions for subgroups based on NYHA functional class and race. INTERPRETATION: The effects of empagliflozin and dapagliflozin on hospitalisations for heart failure were consistent in the two independent trials and suggest that these agents also improve renal outcomes and reduce all-cause and cardiovascular death in patients with HFrEF. FUNDING: Boehringer Ingelheim.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020. PMID: 32877652. doi:10.1016/S0140-6736(20)31824-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。